



Information on the Total Number of Voting Rights (Denominator) Following the Completion of the LDA Capital Increase

Liege, Belgium, 30 June 2022 – 17:45 CEST – In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the "Company" or "Mithra") announces the below information, following the issuance of 625,000 new shares today for a total amount of EUR 4,133,933 following the Put Option Notice issued on 13 May, 2022¹ in the framework of LDA capital commitment agreement entered into April 2020² and extended in April 2022³.

As a reminder, LDA Capital commits an amount of up to EUR 75 million in cash within a maximum of five years in exchange for new ordinary shares in Mithra. This is the fourth put option notice related to this agreement, leaving EUR 49 million available to Mithra.

Following this capital increase's completion, Mithra now has 50,582,125 outstanding shares carrying voting rights (49,957,125 outstanding shares carrying voting rights previously).

Therefore, Mithra publishes the following updated information:

- Capital: EUR 37,030,953.40
- Total number of securities carrying voting rights: 50,582,125 (all ordinary shares)
- Total number of voting rights (= denominator): 50,582,125 (all relating to ordinary shares)
- Number of outstanding rights to subscribe to securities carrying voting rights:
 - Pursuant to the share option plan of 5 November 2018: 1,394,900 subscription rights giving right to 1,394,900 ordinary shares
 - Pursuant to the share option plan of 22 July 2020 : 690,000 subscription rights giving right to 690,000 ordinary shares
 - Pursuant to the share option plan granted to the lending shareholders of 7 September 2020: 300,000 subscription rights giving right to 300,000 ordinary shares
 - Pursuant to the share option plan of 20 November 2020: 390,717 subscription rights giving rise to 390, 717 ordinary shares.

¹ [Mithra Press release \(13/05/2022\)](#)

² [Mithra Press release \(24/04/2020\)](#)

³ [Mithra Press release \(18/04/2022\)](#)

For more information, please contact:**Benoît Mathieu (IRO)** : +32 473 35 80 18 – investorrelations@mithra.com**Maud Vanderthommen (Press)** : +32 473 58 61 04 – press@mithra.com**About Mithra**

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle®, Mithra is now focusing on its second product Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium.

www.mithra.com

Donesta® is a registered trademark of Mithra Pharmaceuticals or one of its affiliates.

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates", "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

**News
Alerts**

Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media :

[Linkedin](#) • [Twitter](#) • [Facebook](#)